OsajinCAS# 482-53-1 |
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 482-53-1 | SDF | Download SDF |
| PubChem ID | 95168 | Appearance | Yellow powder |
| Formula | C25H24O5 | M.Wt | 404.5 |
| Type of Compound | Flavonoids | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | 5-hydroxy-3-(4-hydroxyphenyl)-8,8-dimethyl-6-(3-methylbut-2-enyl)pyrano[2,3-h]chromen-4-one | ||
| SMILES | CC(=CCC1=C(C2=C(C3=C1OC(C=C3)(C)C)OC=C(C2=O)C4=CC=C(C=C4)O)O)C | ||
| Standard InChIKey | DCTLJGWMHPGCOS-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C25H24O5/c1-14(2)5-10-17-21(27)20-22(28)19(15-6-8-16(26)9-7-15)13-29-24(20)18-11-12-25(3,4)30-23(17)18/h5-9,11-13,26-27H,10H2,1-4H3 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. Osajin shows antitumor activity in different tumor cell lines. 2. The cardioprotection provided by Osajin treatment results from the suppression of oxidative stress and correlates with the improved ventricular function. 3. Osajin induces apoptosis in human NPC cells through multiple apoptotic pathways, including the extrinsic death receptor pathway, and intrinsic pathways relying on mitochondria and endoplasmic reticulum stress. |
| Targets | P450 (e.g. CYP17) | Bcl-2/Bax | Caspase |
Osajin Dilution Calculator
Osajin Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.4722 mL | 12.3609 mL | 24.7219 mL | 49.4438 mL | 61.8047 mL |
| 5 mM | 0.4944 mL | 2.4722 mL | 4.9444 mL | 9.8888 mL | 12.3609 mL |
| 10 mM | 0.2472 mL | 1.2361 mL | 2.4722 mL | 4.9444 mL | 6.1805 mL |
| 50 mM | 0.0494 mL | 0.2472 mL | 0.4944 mL | 0.9889 mL | 1.2361 mL |
| 100 mM | 0.0247 mL | 0.1236 mL | 0.2472 mL | 0.4944 mL | 0.618 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Isobergapten
Catalog No.:BCN2377
CAS No.:482-48-4
- Isoimperatorin
Catalog No.:BCN5897
CAS No.:482-45-1
- Imperatorin
Catalog No.:BCN5574
CAS No.:482-44-0
- Afzelin
Catalog No.:BCN5573
CAS No.:482-39-3
- Kaempferitrin
Catalog No.:BCN5572
CAS No.:482-38-2
- Hyperoside
Catalog No.:BCN5570
CAS No.:482-36-0
- Isoquercitrin
Catalog No.:BCN5569
CAS No.:482-35-9
- Isopimpinellin
Catalog No.:BCN5568
CAS No.:482-27-9
- Byakangelicin 2'-O-Isovalerate
Catalog No.:BCC8899
CAS No.:108006-56-0
- Homoferreirin
Catalog No.:BCN4765
CAS No.:482-01-9
- Estriol 3-sulfate
Catalog No.:BCN2236
CAS No.:481-95-8
- Chrysophanol
Catalog No.:BCN5567
CAS No.:481-74-3
- Sarpagine
Catalog No.:BCN5575
CAS No.:482-68-8
- Nordalbergin
Catalog No.:BCC8344
CAS No.:482-82-6
- Dalbergin
Catalog No.:BCN7452
CAS No.:482-83-7
- Indigo
Catalog No.:BCN1091
CAS No.:482-89-3
- Aricine
Catalog No.:BCN5576
CAS No.:482-91-7
- RG 108
Catalog No.:BCC1134
CAS No.:48208-26-0
- Tetrahydroamentoflavone
Catalog No.:BCN5571
CAS No.:48236-96-0
- 14-Dehydrobrowniine
Catalog No.:BCN8109
CAS No.:4829-56-5
- Ajmalicine
Catalog No.:BCN5577
CAS No.:483-04-5
- Isorauhimbine
Catalog No.:BCN5578
CAS No.:483-09-0
- 9-Hydroxycalabaxanthone hydrate
Catalog No.:BCC5325
CAS No.:483-14-7
- Dihydroberberine
Catalog No.:BCN2573
CAS No.:483-15-8
[Protective effects of the flavonoids osajin and pomiferin on heart ischemia-reperfusion].[Pubmed:16921735]
Ceska Slov Farm. 2006 Jul;55(4):168-74.
The study was undertaken to evaluate the cardioprotective potential of the flavonoids Osajin and pomiferin against ischemia-reperfusion induced injury in rat hearts as a model of antioxidant-based composite therapy. Studies were performed with isolated, modified Langendorff-perfused rat hearts and ischemia of the heart was initiated by stopping the coronary flow for 30 min followed by 60 min of reperfusion (14 ml x min(-1)). Wistar rats were divided into four groups. The treated groups received Osajin or pomiferin (5 mg/kg/day in 0.5% Avicel), the placebo group received only 0.5 Avicel; the intact group was left without any applications. Biochemical indicators of oxidative damage--malondialdehyde, superoxide dismutase, glutathione peroxidase, total antioxidant activity in serum and the myocardium have been evaluated. We also examined the effect of Osajin and pomiferin on cardiac function: left ventricular end-diastolic pressure, left ventricular pressure, and peak positive dP/dt. Our results demonstrate that the flavonoids Osajin and pomiferin attenuate the myocardial dysfunction provoked by ischemia-reperfusion. This was confirmed by an increase in both the antioxidant enzyme values and the total antioxidant activity. The cardioprotection provided by Osajin and pomiferin treatment results from the suppression of oxidative stress and correlates with the improved ventricular function.
Activation of multiple apoptotic pathways in human nasopharyngeal carcinoma cells by the prenylated isoflavone, osajin.[Pubmed:21532751]
PLoS One. 2011 Apr 12;6(4):e18308.
Osajin is a prenylated isoflavone showing antitumor activity in different tumor cell lines. The underlying mechanism of Osajin-induced cancer cell death is not clearly understood. In the present study, the mechanisms of Osajin-induced cell death of human nasopharyngeal carcinoma (NPC) cells were explored. Osajin was found to significantly induce apoptosis of NPC cells in a dose- and time-dependent manner. Multiple molecular effects were observed during Osajin treatment including a significant loss of mitochondrial transmembrane potential, release of cytochrome c into the cytosol, enhanced expression of Fas ligand (FasL), suppression of glucose-regulated protein 78 kDa (GRP78), and activation of caspases-9, -8, -4 and -3. In addition, up-regulation of proapoptotic Bax protein and down-regulation of antiapoptotic Bcl-2 protein were also observed. Taken together, Osajin induces apoptosis in human NPC cells through multiple apoptotic pathways, including the extrinsic death receptor pathway, and intrinsic pathways relying on mitochondria and endoplasmic reticulum stress. Thus, Osajin could be developed as a new effective and chemopreventive compound for human NPC.
Protective effects of osajin in ischemia-reperfusion of laboratory rat kidney.[Pubmed:16826976]
Pharmazie. 2006 Jun;61(6):552-5.
The aim of this study was to analyze the antioxidative effect of Osajin during prophylactic administration. The pathological model for in vivo experiment was the unilateral ischemia-reperfusion of kidney of the laboratory rat. The animals were randomly divided into five groups. Osajin was administrated orally in doses of 5, 10 and 20 mg/kg once a day to three premedicated groups. Placebo--0.5% solution of Avicel--was given to the fourth group and the fifth group was completely intact. The premedication lasted 15 days and subsequently the ischemia of the left kidney was incited in general anaesthesia for 60 min. The reperfusion lasted 10 min and it was finished by blood collection from the left ventricle and the reperfused kidney was recovered. Selected biochemical markers were assessed in blood: superoxide dismutase, glutathion peroxidase, total antioxidative capacity and malondialdehyde. The kidney tissue samples were used for histopathological examination. Laboratory and histopathological results confirmed supposed effects of Osajine. The dependence between the effect and the applied dose of Osajin was linear. The best biochemical results were reached after administration of Osajin at the dose of 5 mg/kg. The best histopathological results were reached after administration of Osajin at the dose of 10 mg/kg.
Effects of prenylated isoflavones osajin and pomiferin in premedication on heart ischemia-reperfusion.[Pubmed:16936909]
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2006 Jul;150(1):93-100.
The present 15 days study was undertaken to evaluate the cardioprotective potential of the prenylated isoflavones Osajin and pomiferin isolated from the infructences of Maclura pomifera, Moraceae, against ischemia-reperfusion induced injury in rat hearts as a model of antioxidant-based composite therapy. The study was performed on isolated, modified Langendorff-perfused rat hearts and the ischemia of heart was induced by stopping coronary flow for 30 min followed by 60 min of reperfusion (14 ml min(-1)). The Wistar rats were divided into four groups. The first treatment group received Osajin (5 mg/kg/day in 0.5% Avicel); the second treatment group received pomiferin (5 mg/kg/day in 0.5% Avicel); the placebo group received only 0.5 Avicel; the last was an untreated control group. Biochemical indicator of oxidative damage-lipid peroxidation product malondialdehyde, antioxidant enzymes - superoxide dismutase, glutathione peroxidase, total antioxidant activity in serum and myocardium were evaluated. The effect of Osajin and pomiferin on cardiac function, left ventricular end-diastolic pressure, left ventricular pressure and peak positive +dP/dt ischemia and reperfusion, also was examined. The results demonstrate that Osajin and pomiferin attenuates the myocardial dysfunction provoked by ischemiareperfusion. This was confirmed by an increase in both antioxidant enzyme values and total antioxidant activity. The cardioprotection provided by Osajin and pomiferin treatment results from the suppression of oxidative stress and this correlates with improved ventricular function.
Effect of osajin and pomiferin on antidiabetic effects from normal and streptozotocin-induced diabetic rats.[Pubmed:25632468]
Nat Prod Commun. 2014 Dec;9(12):1723-4.
The present study evaluated the antidiabetic effect of Osajin and pomiferin from the Osajin orange in normal and streptozotocin-induced diabetic rats. Pomiferin in the streptozotocin-induced diabetic effects showed significant hypoglycemic activity for 14 days significantly decreased the serum glucose, triglyceride while it increased the serum insulin in diabetic rats but not in normal rats (p < 0.05; at doses of 100 and 300 mg/kg for 14 days). Pomiferin showed potential in anti-diabetic effects compared to Osajin. It also has no effects on C-peptide (ECLIA). Further structure-activity relationships of aromatic position 3 on ring B from Osajin and pomiferin will be reported in due course.
